top of page

ICON plc

ICON plc is a global provider of clinical research and healthcare intelligence.
It partners with pharmaceutical and biotech companies to advance drug development.

ICON plc stock investing summary image

Join Our Programs

Our clients trust us for our expert advice and in-depth market analysis. Discover our services to gain more knowledge on investing.

Growth Stock Analysis

Join our comprehensive growth stock analysis course designed for savvy investors. Learn how to evaluate stocks with a proven track record of delivering value and understand their potential for growth. Enhance your investment strategies with our expert-led insights.

Finance News Webinar

Join our Finance News Webinar for a clear breakdown of the most important financial stories shaping the markets today. We turn complex headlines into actionable insights, helping you understand what truly matters — and why.

Stock Market Webinar

Join our Stock Market Webinar to gain clear, actionable insights into current market trends. Learn how to analyse data, interpret signals, and make informed investment decisions with confidence. Designed for both beginners and experienced investors, this session delivers practical knowledge you can apply immediately.

Stock Analysis

Performance

​ICON plc reported strong financial performance in 2024, achieving a 2.0% year-over-year increase in revenue to $8.28 billion and a 28.8% rise in GAAP net income to $791.5 million. Adjusted net income for the year was $1.16 billion, or $14.00 per diluted share, reflecting a 9.5% increase from the previous year. The company also generated $1.1 billion in free cash flow and repurchased $500 million in stock, demonstrating robust cash management and shareholder value initiatives. Looking ahead, ICON has reaffirmed its 2025 revenue guidance of $8.05–$8.65 billion and adjusted EPS guidance of $13.00–$15.00.​

Quality of Earnings

The company demonstrates strong adherence to General Accounting Principles, with financial reports that conform to GAAP, are decision-useful, sustainable, and offer returns exceeding the cost of capital. There have been no recent changes to accounting policies, and all required financial reports are submitted on time. Revenue quality is also robust, marked by high predictability—with a substantial portion of clients returning year after year—strong profitability with gross margins exceeding 70%, diversified income sources with no client accounting for more than 15% of revenue, and clear growth in both revenue and net income. Additionally, there are no significant financial report warning signs: earnings contain minimal accrual components, do not narrowly beat benchmarks in a suspicious pattern, and revenue is not recognized prematurely. Expenses are not misrepresented, audit opinions are unqualified, goodwill is properly assessed, and the company does not rely on aggressive accounting tactics such as related-party transactions or off-balance-sheet debt. Operating ccash flows align with net income, earnings are recurring and persistent, and there is no history of restatements or enforcement actions, reinforcing the reliability and quality of the company’s financial reporting.

Financial Data Chart Company for Stock Analysis

Company Summary

ICON plc is a leading global contract research organization (CRO) headquartered in Dublin, Ireland, providing outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, ICON has grown to employ over 41,900 people across 106 locations in 55 countries.

Company Stock Analysis
bottom of page